SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- Etern BioPharma (Shanghai) Co., Ltd
- Target Recruit Count
- 34
- Registration Number
- NCT05525559
- Locations
- 🇺🇸
BUMC - Mary Crowley Cancer Research Centers (MCCRC), Dallas, Texas, United States
FGFR Inhibitor ET0111 Monotherapy in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2022-10-04
- Lead Sponsor
- Etern BioPharma (Shanghai) Co., Ltd
- Target Recruit Count
- 37
- Registration Number
- NCT05522309
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhejiang university school of medicine, Hangzhou, Zhejiang, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Beijing Tongren Hospital,CMU, Beijing, Beijing, China
SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Etern BioPharma (Shanghai) Co., Ltd
- Target Recruit Count
- 37
- Registration Number
- NCT05354843
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳West China School of Medicine/West China Hospital of Sichuan University, Chengdu, Sichuan, China
© Copyright 2025. All Rights Reserved by MedPath